Advanced Medical Solutions (AIM:AMS) FDA approval enhances the appeal
The FDA has approved two new product claims for the Group’s octyl formulation product, LiquiBand Exceed™ giving it a competitive advantage in the topical skin adhesive market.
The two new claims include the use of a single device to cover wounds of up to 30cm, as well as a single device being suitable for intraoperative reuse for up to 90 minutes on a single patient. Both…
Previous article Next article